Havana, 6 Dec (EFE).-the therapeutic vaccine against the lung cancer CIMAVax-EGF, created in Cuba, has been more than 2,000 people of the island and is projected to employ the same principle for prostate cancer, also reported today means premises.
According to health authorities cited Tuesday by the official press, this vaccine “is a safe therapy for cancer, with very few adverse States and increased life expectancy and quality of life” of the patient.
Gisela Gonzalez, Ph.d. in biological sciences and pioneer of the project, announced, in statements to the Agency for national information (AIN), working on clinical trials for the vaccine against prostate cancer and is expected to be registered for that use in 2012.
CIMAVax-EGF is registered in Cuba and Peru, in the process of registration in Brazil, Argentina or Colombia, among other Nations, and has the right of patent in almost all the world.
Recently transcendió on the island United Kingdom apply in the coming weeks a trial of this vaccine Therapeutics.
The drug was developed after 15 years of research by scientists at the center of Molecular Immunology (CIM) of Cuba, those who believe that the same principle of the drug could be used in the treatment of oncological illnesses.
The drug may not prevent disease but allows you to control advanced cancer to generate antibodies against proteins that trigger the slippage in the processes of proliferation cell.
According to data from the World Health Organization, cancer is the leading cause of mortality worldwide, and the lung is one of the of greatest incidence.
In 2010 Cuba registered more than 22,000 deaths by oncogenic tumors, according to official data. EFE
